The current study was conducted on Riverine-type buffaloes naturally exposed to Sub-clinical Mastitis (SCM). Probiotic bacteria like Lactobacillus rhamnosus GG primarily exert their benefits by competing with harmful bacteria for nutrients and adhesion sites, producing beneficial metabolites, and modulating the immune response. Platelet-Rich Plasma (PRP) comprises various growth factors and cytokines that can modulate the inflammatory response by promoting anti-inflammatory cytokines and inhibiting pro-inflammatory cytokines, thus helping to downregulate excessive inflammation. A total of 96 udder quarters/teats were randomly allotted for three treatment groups, i.e., Probiotic group (n=32), Probiotic plus Platelet-Rich Plasma (PRP) group (n=32), and Antibiotic group (n=32). The probiotic and antibiotic were purchased from the local market. PRP was prepared from the whole blood of the recipient animal. All the treatments were administered intra-mammary to affected animals. Somatic Cell Count (SCC) was significantly (p<0.05) decreased in animals that received Probiotic and PRP. The Probiotic alone was nine times more efficient than antibiotic alone, Probiotic plus PRP was 12.43 times more fecund than antibiotic alone and Probiotic plus PRP was 38.1% more prolific than Probiotic alone. Receiver Operating Characteristic (ROC) analysis demonstrated an acceptable predictive value (0.77) for the area under the curve when assessing the effectiveness of Probiotic plus PRP as a substitute for antibiotics in Sub-clinical Bubaline Mastitis. The non-parametric Kruskal-Wallis test revealed a significant difference (p<0.05) in the mean rank difference among the three treatment groups. In conclusion, the use of Lactobacillus rhamnosus GG and PRP in the management of Sub-clinical Bubaline Mastitis shows promise as a potential therapeutic agent by reducing somatic cell count and inhibiting the growth of mastitis-causing bacteria.